Analysis of CHK2 in Vulval Neoplasia
Author Information
Author(s): Reddy A, Yuille M, Sullivan A, Repellin C, Bell A, Tidy J A, Evans D J, Farrell P J, Gusterson B, Gasco M, Crook T
Primary Institution: Ludwig Institute for Cancer Research, Imperial College Faculty of Medicine
Hypothesis
Is CHK2 mutated in vulval cancers and does it co-exist with p53 mutations?
Conclusion
CHK2 is a target for somatic mutation in a small proportion of vulval cancers, but its mutation does not commonly substitute for p53 inactivation.
Supporting Evidence
- Somatic mutations in CHK2 were found in two out of 40 cases of vulval squamous cell carcinomas.
- Both mutations in CHK2 occurred in the kinase domain, likely compromising its function.
- CHK2 mutations co-exist with p53 mutations in the studied vulval cancers.
- No methylation was detected in the CHK2 promoter in any of the 40 vulval SCC analyzed.
- CHK2 expression was not lost in any of the vulval cancers studied.
Takeaway
This study looked at a gene called CHK2 in vulval cancer and found that some cancers have changes in this gene, but it doesn't usually replace the role of another important gene called p53.
Methodology
The study analyzed CHK2 mutations in vulval squamous cell carcinomas and vulval intraepithelial neoplasia using genomic DNA and RNA sequencing.
Limitations
The study only examined a small number of cases and may not represent all vulval cancers.
Participant Demographics
The study included 72 individuals with vulval neoplasia, with specific focus on 40 cases of vulval squamous cell carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website